Skip to main content

June 2016, Vol 6, No 6


The first oncology biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin. Read More ›








Page 2 of 2